Navigation Links
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
Date:2/4/2013

noma.  This study was recently posted on ClinicalTrials.gov and has a scheduled start date of April 2013.  Please click here to view. Novartis has also recently accelerated its goal of regulatory submissions for MEK162 to 2015.  In addition, Novartis announced plans to pursue additional clinical development in combination with a Raf inhibitor in BRAF mutant melanoma.

Selumetinib – AstraZeneca may initiate Phase 3 trial in 2013AstraZeneca recently announced with their quarterly financial results that they expect to initiate a Phase 3 selumetinib trial in 2013 in patients with NSCLC.  Selumetinib is advancing in 65 trials, 39 of which are in Phase 2.  AstraZeneca initiated a 225-patient Phase 2 randomized trial with selumetinib in combination with docetaxel in 2nd line unselected NSCLC.  The trial will evaluate two different doses of docetaxel with selumetinib versus docetaxel alone.  We believe this will help optimize the product's profile, validate biomarker diagnostics and generate preliminary efficacy in selective subsets of NSCLC patients. Additionally, AstraZeneca will specifically assess efficacy within KRAS subgroups in terms of progression free survival, overall survival, overall response rate and change in tumor size at week 6.

In addition to NSCLC, positive results were presented last year with selumetinib in thyroid and ovarian cancers.  In a Phase 2 trial in recurrent low-grade serous ovarian or peritoneal cancer, patients taking selumetinib showed a disease control rate of 81%, defined as either complete or partial response or progression-free survival or progression-free survival of greater than 6 months.  Eight patients had complete (1) or partial (7) responses.  The median survival rate without cancer progression was 11 months.  And in patients with thyroid cancer, selemetinib showed a 71%
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
2. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
3. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
4. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
7. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
8. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
9. John A. Orwin Joins Array BioPharma Board Of Directors
10. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
11. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... According to a new market research ... Forecasts (2015-2020), , published by Mordor Intelligence, the Global market ... end of 2020, with North America ... of the global market size. The Global market for Stem ... during the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) ...
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional ... China , as well as solid contributions from Korea, India ... / Middle East / Africa ... Germany , Turkey and the United ... grew 11%, excluding U.S. HPV sales, on demand across all customer classes. The ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
(Date:7/29/2015)... ... 29, 2015 , ... G-CON Manufacturing, Inc., the leading prefabricated ... generation cell therapy POD® design. The 2nd generation portfolio not only delivers design ... POD® design. , “G-CON first offered our miniPOD CT product line to ...
Breaking Biology Technology:Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
... DuPont Leader at UN Food and ... Agriculture Conference, ROME, June 3 ... harvest from their land and help address the,strong and growing global demand ... Pioneer Hi-Bred, told a United Nations Food and,Agriculture Organization Conference being held ...
... JOLLA, Calif., June 3 DermTech, a biotechnology,company ... and other diseases, today announced that Herbert A. ... Fritsche is,Professor and Chief of Clinical Chemistry at ... experts in the development and validation of cancer,diagnostics ...
... GeneXpert(R) Test Menu in Canada and Mexico, ... announced that Health Canada issued a medical device ... Group B Streptococcus (GBS),and Xpert(TM) EV (enterovirus), for ... Xpert MRSA, which received Health Canada,license in January ...
Cached Biology Technology:More Can Be Done Now to Address the Growing Global Demand for Grain 2More Can Be Done Now to Address the Growing Global Demand for Grain 3DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advisory Board 2Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 2Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 3Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico 4
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
(Date:7/20/2015)... -- Acuity Market Intelligence,s latest research "The Global Biometrics ... Privacy" forecasts that between 2014 and 2020 nearly ... to smart mobile devices by 2.2 billion mobile ... to generate more than $67.9 billion in total ...    "Biometrics is at the center ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... attacks in New York City prompted large increases in ... man-made and natural disasters. But, this funding has ... disaster funding distribution is deeply inefficient: huge cash infusions ... abruptly after interest wanes. These issues have exposed significant ...
... damage to the Fukushima 1 Nuclear Power Plant in 2011, ... of radioactive contamination on wild and cultivated plants. In a ... these experts examine the potential adverse effects of radioactivity on ... article focusing on the efforts of a research group led ...
... treat certain types of cancer protect the insulin-producing cells ... mellitus type 1 in mice. The medicine works by ... have been made by researchers from the University of ... of Southern Denmark working with researchers in Belgium, Italy, ...
Cached Biology News:Funding problems threaten US disaster preparedness 2Microalgae and aquatic plants can help to decrease radiopollution in the Fukushima area 2Cancer drug protects against diabetes 2
... wide range of next-generation features into a ... standard for flexible laboratory solutions. It puts ... pipetting, dilution, dispensing, and integrations into ... and flexible as it is efficient and ...
... The mini incubation trays ... used to screen antigens that ... membrane. Each tray has eight ... channels that accommodate strips cut ...
... the process and you reduce the chance ... the CEQ 8000. Developed using Beckman Coulters ... in capillary electrophoresis technology, the CEQ 8000 ... This system automatically fills the capillary array ...
... standard electrophoresis hood is a ... systems. Placed on the transilluminator, ... place and provides a darkroom ... the lab bench. This 13 ...
Biology Products: